<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747315</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0710</org_study_id>
    <nct_id>NCT03747315</nct_id>
  </id_info>
  <brief_title>A Diagnostic Test for Familial Mediterranean Fever</brief_title>
  <acronym>DEPIST-FMF</acronym>
  <official_title>Assessment of a Functional Test to Detect Familial Mediterranean Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence:
      1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the
      Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing
      pro-inflammatory cytokines (interleukin-1β).

      In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome
      (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in
      FMF patients compared to subjects with a similar clinical picture, and healthy controls. In
      addition, a measure of cell death yielded significant results in differentiating patients
      from controls.

      The investigators hypothesize that this fast and simple functional test can serve as a
      diagnostic tool for FMF.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in interleukin-1bβ levels</measure>
    <time_frame>Less than 48 hours</time_frame>
    <description>Quantification of the capacity of interleukin-1β concentration measured in primary monocyte supernatants in response to kinase inhibitors, to discriminate Familial Mediterranean Fever subjects from control subjects (healthy subjects and subjects with symptoms similar to those of Familial Mediterranean Fever).
Analysis have to be performed Less than 48 hours after blood sampling (only one sampling).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Familial Mediterranean Fever</condition>
  <arm_group>
    <arm_group_label>Familial Mediterranean Fever (patients)</arm_group_label>
    <description>Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (patients)</arm_group_label>
    <description>Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy donors</arm_group_label>
    <description>Patients without symptoms (anonymous blood donors)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>In vitro functional test</intervention_name>
    <description>Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.</description>
    <arm_group_label>Control group (patients)</arm_group_label>
    <arm_group_label>Familial Mediterranean Fever (patients)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>In vitro functional test</intervention_name>
    <description>Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.</description>
    <arm_group_label>Healthy donors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Familial Mediterranean Fever, patients controls with similar symptoms and
        healthy subjects who donated their blood to the French Blood Establishment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical picture compatible with an Familial Mediterranean Fever and an earlier
             genetic analysis finding a mutation of the MEFV gene;

          -  Newly diagnosed or undergoing follow-up (without criteria of delay or evolutionary
             stage);

          -  In the course of specific or non-specific treatment of the disease or without
             treatment;

          -  For whom a blood test is planned as part of the routine care;

          -  Of whom the informed non-opposition has been collected (parental authorization in the
             case of a minor patient);

        Exclusion Criteria:

          -  patient under legal protection or under safeguard of justice or any other measures of
             protection (guardianship, curatorship);

          -  Person unable to express his consent;

          -  Person in emergency situation, vital or not;

          -  Infection known to HIV and / or HBV and / or HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yvan JAMILLOUX, Dr</last_name>
    <phone>04 26 73 26 36</phone>
    <phone_ext>+33</phone_ext>
    <email>yvan.jamilloux@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de néphrologie et rhumatologie pédiatrique, Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre BELOT, Dr</last_name>
      <phone>04.27.85.61.26</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandre.belot@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unité Inserm U1111 &amp; Service de Médecine Interne, Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yvan JAMILLOUX, Dr</last_name>
      <phone>04.26.73.26.36</phone>
      <phone_ext>+33</phone_ext>
      <email>yvan.jamilloux@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne, Pavillon O - Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas BARBA, Dr</last_name>
      <email>thomas.barba@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne et pathologies vasculaires, Batiment 1B, Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Christophe LEGA, Pr</last_name>
      <email>jean-christophe.lega@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brucellosis</mesh_term>
    <mesh_term>Familial Mediterranean Fever</mesh_term>
    <mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

